Watching the DiPG video trialing 3 drugs including Pax on 240 patients (randomised) - if the application of the 3 drugs is equally weighted then…
Pax is in 150 odd GBM stage 1 + the original 30 + another 80 odd DiPG + all other concurrent trials so the drug is getting into a serious number of patients collectively.
Good to be reminded we hold an orphan drug designation ODD in both adults for GBM and children in DiPG.
Next week should be a better week when more of the fearful begin to calm down and re remember all of the work pushing us forward across 9 different focuses.
And that we do have a drug performing better than the standard of care by a considerable amount and work in 60% more patients and now providing data in a year from a 150 odd patients.
Eyes on the ball - multiple shots on goal.
